二价HPV疫苗对女性肛门口HPV阳性的效果
该研究在荷兰548名16-24岁女性STI门诊就诊者中开展重复横断面调查,估计二价HPV疫苗至少1剂对肛门口HPV阳性的疫苗有效性。结果显示,针对HPV-16/18的疫苗有效性为89.9%(95%CI 63.0%-97.2%),型别特异性疫苗有效性与宫颈阴道HPV疫苗有效性高度相关(Spearman ρ=0.76)。
要点
- 二价HPV疫苗至少1剂对肛门口HPV-16/18阳性的疫苗有效性为89.9%。
- 型别特异性疫苗有效性与宫颈阴道HPV疫苗有效性相关(Spearman ρ=0.76)。
- 提示HPV-16/18疫苗接种对生殖道和肛门感染的效果可能相当。
核心结论
- 二价HPV疫苗至少1剂对16-24岁女性STI门诊就诊者肛门口HPV-16/18阳性具有较高疫苗有效性。
研究设计与样本
- 重复横断面调查,纳入548名16-24岁女性STI门诊就诊者,均提供肛拭子样本。
主要发现
- 至少1剂二价疫苗对肛门口HPV-16/18阳性的疫苗有效性为89.9%(95%CI 63.0%-97.2%)。
- 型别特异性疫苗有效性与宫颈阴道HPV疫苗有效性高度相关(Spearman ρ=0.76)。
关键数值与推荐
- 疫苗有效性定义为至少1剂二价疫苗对肛门口HPV阳性的效果。
- HPV-16/18与约90%的HPV相关肛门癌相关。
临床怎么用
- 支持将二价HPV疫苗接种作为女性肛门HPV感染及肛门癌预防的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV-16/18 are associated with approximately 90% of HPV-related anal cancers. Among 548 female STI clinic visitors 16-24 years old who provided an anal swab sample as part of a repeated cross-sectional survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman ρ = 0.76), suggesting comparable effectiveness of HPV-16/18 vaccination against genital and anal infections.
引用
- Woestenberg PJ, King AJ, Van Benthem BHB, et al. Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands. J Infect Dis. 2020. PMID: 31100134. doi:10.1093/infdis/jiz187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。